Baseline characteristics of study population after matching
| Characteristics . | Ibrutinib (n = 944) . | Acalabrutinib (n = 944) . | P value . |
|---|---|---|---|
| Age at index, mean (SD), y | 70.3 (10.3) | 70.3 (10.6) | .933 |
| Sex, male, n (%) | 551 (58.4) | 553 (58.6) | .925 |
| Race, White, n (%) | 776 (82.9) | 752 (79.6) | .159 |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 765 (81.0) | 748 (79.2) | .32 |
| Unknown ethnicity | 158 (16.7) | 172 (18.2) | .39 |
| Previous treatment, n (%) | |||
| Venetoclax∗ | 16 (1.8) | 19 (2.5) | .32 |
| Rituximab∗ | 71 (8.0) | 75 (8.5) | .729 |
| Obinutuzumab∗ | 17 (1.9) | 19 (2.0) | .86 |
| Other characteristics, n (%) | |||
| Diabetes mellitus | 116 (12.3) | 123 (12.0) | .628 |
| BMI 30-39 | 222 (23.5) | 223 (23.6) | .821 |
| BMI >39 | 50 (5.6) | 47 (4.97) | .605 |
| Atrial fibrillation† | 93 (10.58) | 92 (10.46) | .93 |
| Characteristics . | Ibrutinib (n = 944) . | Acalabrutinib (n = 944) . | P value . |
|---|---|---|---|
| Age at index, mean (SD), y | 70.3 (10.3) | 70.3 (10.6) | .933 |
| Sex, male, n (%) | 551 (58.4) | 553 (58.6) | .925 |
| Race, White, n (%) | 776 (82.9) | 752 (79.6) | .159 |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 765 (81.0) | 748 (79.2) | .32 |
| Unknown ethnicity | 158 (16.7) | 172 (18.2) | .39 |
| Previous treatment, n (%) | |||
| Venetoclax∗ | 16 (1.8) | 19 (2.5) | .32 |
| Rituximab∗ | 71 (8.0) | 75 (8.5) | .729 |
| Obinutuzumab∗ | 17 (1.9) | 19 (2.0) | .86 |
| Other characteristics, n (%) | |||
| Diabetes mellitus | 116 (12.3) | 123 (12.0) | .628 |
| BMI 30-39 | 222 (23.5) | 223 (23.6) | .821 |
| BMI >39 | 50 (5.6) | 47 (4.97) | .605 |
| Atrial fibrillation† | 93 (10.58) | 92 (10.46) | .93 |